Diabeloop announced today that it set up a local and dedicated team to support its pursuit of entry into the U.S. market.
Paris-based Diabeloop develops an automated insulin delivery (AID) system that deployed throughout Europe this past year, making it commercially available in Germany, the Netherlands, Italy, Spain and Switzerland, with more countries to come. The interoperable controller can be used recombination with the Dexcom G6 CGM and Accu-Chek Insight insulin pump and will soon be available with ViCentra’s patch-like Kaleido pump.
According to a news release, the company seeks to build upon its commercialization efforts by entering into the U.S. market with a U.S. based team established to support future FDA applications. The company was also invited into the American Association of Clinical Endocrinologists (AACE) corporate advisory program, increasing access to diabetes leaders and offering strong relationships with other diabetes partners in the U.S.
“We are thrilled to welcome Diabeloop to our Corporate AACE Partnership (CAP) program,” AACE director of relationships Glenn Sebold said in the release. “Our mission at AACE is elevating clinical endocrinology to improve global health, and our CAP program supports this by ensuring there is an open dialogue between industry and our association to advance patient care and find ways we can improve.”
Diabeloop co-CEO Marc Julien said the company believes that working with U.S.-based physicians, patient organizations and partners is key to penetrating the market.
“We are very honored to join the AACE CAP,” Julien said. “Diabeloop is dedicated to bringing individualized, easy-to-use diabetes management solutions to patients. … We also have built a dedicated team, based locally to accurately understand the U.S. market.”
Senior VP of North America, Zoe Heineman, will lead Diabeloop’s newly formed U.S. team. Dr. Nicholas Argento, Jason C. Baker, David M. Harlan, Camillo Ricordi and Paul Strumph were appointed as scientific advisors to the U.S. advisory board as well.
“Diabeloop is becoming known in the U.S. for being able to do more for even the most complex cases of diabetes with personalized parameters available in our CE-marked interoperable icontroller, which runs self-learning insulin delivery algorithms using an iCGM and an ACE pump,” Heineman said.